Edition:
United States

StemCells Inc (STEM.O)

STEM.O on Consolidated Issue listed on NASDAQ Capital Market

1.37USD
29 Sep 2016
Change (% chg)

-- (--)
Prev Close
$1.37
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
2,403,422
52-wk High
$7.56
52-wk Low
$0.33

STEM.O

Chart for STEM.O

About

StemCells, Inc. (StemCells) is engaged in the research, development and commercialization of stem cell therapeutics. The Company is focused on developing and commercializing stem and progenitor cells as the basis for therapeutics and therapies. Its lead product development program is its central nervous system (CNS) program, in... (more)

Overall

Beta: -0.16
Market Cap(Mil.): $16.45
Shares Outstanding(Mil.): 12.01
Dividend: --
Yield (%): --

Financials

  STEM.O Industry Sector
P/E (TTM): -- 44.84 37.54
EPS (TTM): -2.80 -- --
ROI: -221.00 -0.27 13.98
ROE: -494.61 -2.93 14.88

BRIEF-Stemcells says respective boards of co and Microbot approved merger agreement

* Respective boards of directors of stemcells and microbot have approved merger agreement - sec filing

Aug 15 2016

StemCells to wind down operations after ending mid-stage study

StemCells Inc said it would wind down operations after the company terminated a mid-stage trial testing its therapy in spinal cord injury, sending its shares plummeting 85 percent.

May 31 2016

UPDATE 2-StemCells to wind down operations after ending mid-stage study

* Shares plunge 85 pct (Adds analyst comment, details; updates shares)

May 31 2016

StemCells terminates mid-stage study; to wind down operations

May 31 StemCells Inc said on Tuesday it had terminated a mid-stage trial in spinal cord injury and that its board had decided to wind down the company.

May 31 2016

BRIEF-StemCells Inc files for rights offering for up to $30 mln

* Files for rights offering for up to $30 million - SEC filing Source text for Eikon: Further company coverage:

May 23 2016

BRIEF-StemCells announces 1-for-12 reverse stock split

* Trading common stock on Nasdaq Capital Market will continue, on a split-adjusted basis, on may 9, 2016 Further company coverage: (Bengaluru Newsroom; +1 646 223 8780; )

May 09 2016

BRIEF-Stemcells announces 1-for-12 reverse stock split

* Trading of common stock on Nasdaq capital market will continue, on a split-adjusted basis, on May 9, 2016 Source text for Eikon: Further company coverage:

May 06 2016

BRIEF-Stemcells Inc announces interim results from cervical spinal cord injury study

* Stemcells inc says presents interim results from its phase ii pathway study in chronic cervical spinal cord injury

Apr 18 2016

Competitors

  Price Chg
Novartis AG (NOVN.S) CHF75.85 -1.40
Pfizer Inc. (PFE.N) $33.32 -0.67
Roche Holding Ltd. (ROG.S) CHF238.50 -3.30
Roche Holding Ltd. (RO.S) CHF239.70 -3.20
Merck & Co., Inc. (MRK.N) $61.91 -1.39
Sanofi SA (SASY.PA) €67.23 -0.80
Abbott Laboratories (ABT.N) $41.44 -0.85
Amgen, Inc. (AMGN.OQ) $165.45 --
Merck KGaA (MRCG.DE) €94.31 -1.57
Biogen Inc (BIIB.OQ) $305.78 --

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : New Constructs, LLC
$25.00
Provider : Thomson Reuters Stock Report
$25.00
Provider : S&P Capital IQ Quantitative Report
$115.00
Provider : Pechala's Reports
$25.00
Provider : Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.